Can a weekly shot reverse type 2 diabetes?

NCT ID NCT07767552

NEW Not yet recruiting Disease control Sponsor: Yanbing Li Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests whether mazdutide, a weekly injection, can help people with type 2 diabetes achieve normal blood sugar levels—a state called remission. Participants are adults with type 2 diabetes who are not well controlled on diet, exercise, or a single medication. They receive either mazdutide or a placebo for about six months, and researchers track how many achieve normal glucose regulation by week 44.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mazdutide, a weekly injection that targets two gut hormones to improve blood sugar control and support weight loss.
What this could lead to: If successful, this could offer a new way to help people with type 2 diabetes achieve remission—meaning their blood sugar returns to normal without needing daily medication.
What could go wrong: This is an early-stage trial, so results may not hold up in larger studies. The treatment may cause side effects, and not everyone may achieve remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS TYPE 2

Contacts and locations

Locations

Sun Yat-sen University (Responsible Party)

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.